SERA - Sera climbs 62% as study for preterm birth test succeeds
- Health diagnostic company Sera Prognostics ( NASDAQ: SERA ) jumped ~62% pre-market Wednesday after announcing that its PreTRM test and physician care met the key goals in a study designed to evaluate its health benefits.
- The AVERT PRETERM TRIAL assessed infant health benefits when pregnancies are screened with the PreTRM test, and physicians act on the test results.
- Disclosing its topline data, Sera ( SERA ) said the study reached the co-primary endpoints indicating a decline in severe neonatal morbidity or death and length of neonatal hospital stay.
- Additionally, there were statistically significant improvements in health outcomes with a PreTRM test-and-treat approach, the company stated, ahead of the peer-reviewed publication of data.
- The trial's active arm involved about 1,500 expectant mothers in ChristianaCare in Delaware, and the control arm was based on historical data obtained from nearly 10,000 patients.
- Seeking Alpha contributor Daron Evans issued a Strong Buy rating on Sera ( SERA ) in August, arguing that the company "has a chance to become standard of care in preterm birth risk screening."
For further details see:
Sera climbs 62% as study for preterm birth test succeeds